These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 14767563)

  • 1. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
    Zhu BT
    Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
    Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG
    Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.
    Müller T
    Int Rev Neurobiol; 2010; 95():49-71. PubMed ID: 21095459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of homocysteine in the treatment of Parkinson's disease.
    Müller T
    Expert Rev Neurother; 2008 Jun; 8(6):957-67. PubMed ID: 18505360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
    Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management for motor and non-motor complications in late Parkinson's disease.
    Chan DK; Cordato DJ; O'Rourke F
    Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should we treat a patient with early Parkinson's disease?
    Tsouli S; Konitsiotis S
    Int J Clin Pract; 2010 Aug; 64(9):1210-9. PubMed ID: 20653797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of functional age on the use of dopamine agonists in patients with Parkinson disease.
    Silver D
    Neurologist; 2006 Jul; 12(4):214-23. PubMed ID: 16832240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis.
    Zhu BT
    Curr Drug Metab; 2002 Jun; 3(3):321-49. PubMed ID: 12083324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa: past, present, and future.
    Hauser RA
    Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease.
    Białecka M; Robowski P; Honczarenko K; Roszmann A; Sławek J
    Neurol Neurochir Pol; 2009; 43(3):272-85. PubMed ID: 19618311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission.
    Napolitano A; Cesura AM; Da Prada M
    J Neural Transm Suppl; 1995; 45():35-45. PubMed ID: 8748607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion.
    Helkamaa T; Reenilä I; Tuominen RK; Soinila S; Väänänen A; Tilgmann C; Rauhala P
    Neurochem Int; 2007; 51(6-7):412-23. PubMed ID: 17573159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.